Levodopa-induced dyskinesia in Parkinson's disease: pathogenesis and emerging treatment strategies
The most commonly used treatment for Parkinson's disease (PD) is levodopa, prescribed in
conjunction with carbidopa. Virtually all patients with PD undergo dopamine replacement …
conjunction with carbidopa. Virtually all patients with PD undergo dopamine replacement …
The pharmacology and clinical pharmacology of 3, 4-methylenedioxymethamphetamine (MDMA,“ecstasy”)
AR Green, AO Mechan, JM Elliott, E O'Shea… - Pharmacological …, 2003 - ASPET
The amphetamine derivative (±)-3, 4-methylenedioxymethamphetamine (MDMA, ecstasy) is
a popular recreational drug among young people, particularly those involved in the dance …
a popular recreational drug among young people, particularly those involved in the dance …
The pharmacology of L-DOPA-induced dyskinesia in Parkinson's disease
l-3, 4-Dihydroxyphenylalanine (l-DOPA) remains the most effective symptomatic treatment of
Parkinson's disease (PD). However, long-term administration of l-DOPA is marred by the …
Parkinson's disease (PD). However, long-term administration of l-DOPA is marred by the …
Molecular mechanisms of L-DOPA-induced dyskinesia
P Jenner - Nature Reviews Neuroscience, 2008 - nature.com
Abstract L-DOPA (l-3, 4-dihydroxyphenylalanine) remains the most effective drug for the
treatment of Parkinson's disease. However, chronic use causes dyskinesia, a complex motor …
treatment of Parkinson's disease. However, chronic use causes dyskinesia, a complex motor …
Coaggregation, cointernalization, and codesensitization of adenosine A2A receptors and dopamine D2Receptors
Antagonistic and reciprocal interactions are known to exist between adenosine and
dopamine receptors in the striatum. In the present study, double immunofluorescence …
dopamine receptors in the striatum. In the present study, double immunofluorescence …
Chronic dopaminergic stimulation in Parkinson's disease: from dyskinesias to impulse control disorders
Dopamine is an essential neurotransmitter for many brain functions, and its dysfunction has
been implicated in both neurological and psychiatric disorders. Parkinson's disease is an …
been implicated in both neurological and psychiatric disorders. Parkinson's disease is an …
Pathophysiology of levodopa-induced dyskinesia: potential for new therapies
E Bezard, JM Brotchie, CE Gross - Nature Reviews Neuroscience, 2001 - nature.com
Involuntary movements—or dyskinesias—are a debilitating complication of levodopa
therapy for Parkinson's disease that is experienced by most patients. Despite the importance …
therapy for Parkinson's disease that is experienced by most patients. Despite the importance …
Levodopa in the treatment of Parkinson's disease: current controversies
CW Olanow, Y Agid, Y Mizuno, A Albanese… - Movement …, 2004 - Wiley Online Library
Levodopa is the most effective symptomatic agent in the treatment of Parkinson's disease
(PD) and the “gold standard” against which new agents must be compared. However, there …
(PD) and the “gold standard” against which new agents must be compared. However, there …
Glutamate NMDA receptor dysregulation in Parkinson's disease with dyskinesias
Levodopa-induced dyskinesias are a common complication of long-term therapy in
Parkinson's disease. Although both pre-and post-synaptic mechanisms seem to be …
Parkinson's disease. Although both pre-and post-synaptic mechanisms seem to be …
Molecular mechanisms and therapeutical implications of intramembrane receptor/receptor interactions among heptahelical receptors with examples from the …
The molecular basis for the known intramembrane receptor/receptor interactions among G
protein-coupled receptors was postulated to be heteromerization based on receptor subtype …
protein-coupled receptors was postulated to be heteromerization based on receptor subtype …